Although systemic therapies for melanoma have been improved, the 5-year survival rate of this aggressive cancer remains poor.
Publications
Governance of Research Melanoma
MRV is a multisite collaboration of clinical and non-clinical researchers, cohort participants and consumers.
Immune checkpoint inhibitors for cancer and venous thromboembolic events
BACKGROUND: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments.
Declining cancer incidence in the elderly: decreasing diagnostic intensity or biology?
BACKGROUND: Advanced age is a consistent risk factor for cancer, nonetheless cancer incidence typically declines after age 75-85 for most solid tumors.